The Clinical Efficacy and Safety of Four-Weekly Docetaxel as First-Line Therapy in Elderly Lung Cancer Patients with Squamous Cell Carcinoma

The Clinical Efficacy and Safety of Four-Weekly Docetaxel as First-Line Therapy in Elderly Lung Cancer Patients with Squamous Cell Carcinoma

Background Docetaxel is one of the standard treatments for advanced non-small cell lung cancer. Docetaxel is usually administered in a 3-week schedule, but there is significant toxicity. In this phase II clinical study, we investigated the efficacy and safety of a 4-weekly schedule of docetaxel mon...

Full description

Bibliographic Details
Main Authors: Jong Hyun Choi, M.D., Juwhan Choi, M.D., Sang Mi Chung, M.D., Jee Youn Oh, M.D., Ph.D., Young Seok Lee, M.D., Ph.D., Kyung Hoon Min, M.D., Ph.D., Gyu Young Hur, M.D., Ph.D., Jae Jeong Shim, M.D., Ph.D., Kyung Ho Kang, M.D., Ph.D., Hyun Kyung Lee, M.D., Ph.D., Sung Yong Lee, M.D., Ph.D.
Format: Article
Language:English
Published: The Korean Academy of Tuberculosis and Respiratory Diseases 2019-07-01
Series:Tuberculosis and Respiratory Diseases
Subjects:
carcinoma
non-small-cell lung
chemotherapy
docetaxel
treatment outcome
safety
therapeutics
aged
lung neoplasms
squamous cell
Online Access:https://www.e-trd.org/search.php?where=aview&id=10.4046/trd.2018.0019&code=0003TRD&vmode=FULL

Internet

https://www.e-trd.org/search.php?where=aview&id=10.4046/trd.2018.0019&code=0003TRD&vmode=FULL

Similar Items